DBV Technologies SA/ US23306J1016 /
2024-04-22 9:59:44 PM | Chg. -0.0207 | Volume | Bid3:28:00 PM | Ask3:28:00 PM | High | Low |
---|---|---|---|---|---|---|
0.6610USD | -3.04% | 43,412 Turnover: 29,136.1095 |
0.6600Bid Size: 100 | 0.7097Ask Size: 5,300 | 0.7218 | 0.6509 |
GlobeNewswire
03-08
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Docu...
GlobeNewswire
03-04
DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
GlobeNewswire
2023-11-09
DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE T...
GlobeNewswire
2023-10-31
DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety...
GlobeNewswire
2023-10-27
DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update
GlobeNewswire
2023-10-16
DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer
GlobeNewswire
2022-03-14
DBV Technologies to Present at the Oppenheimer’s 32nd Annual Healthcare Conference
GlobeNewswire
2022-03-09
DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021 Universal Registration...
GlobeNewswire
2022-03-03
DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates
GlobeNewswire
2022-02-24
DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022
GlobeNewswire
2022-02-14
DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference
GlobeNewswire
2022-01-07
DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference
GlobeNewswire
2021-11-01
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies...
GlobeNewswire
2021-11-01
DBV Technologies to Highlight New Long-term Data from REALISE Trial at ACAAI 2021